Author

Jennifer L. Guerriero

Brigham and Women's HospitalORCID 0000-0002-2104-5457Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 6 Assay:bulk RNA-seq· 5 Research Focus:cell type annotation· 5 Approach:statistical model· 5 Research Focus:differential expression· 4 Research Focus:spatial domain detection· 4 Research Focus:cell-cell communication· 3 Approach:experimental assay· 3

Frequent Co-Authors

Daniel E. MichaudiD· 4 shared Kenichi ShimadaiD· 4 shared Adam NelsoniD· 3 shared Adrienne Gropper WaksiD· 3 shared Carlos Wagner S WanderleyiD· 3 shared Elizabeth Ann MittendorfiD· 3 shared Sara M. TolaneyiD· 3 shared Stuart J. SchnittiD· 3 shared

Activity by Year

2024-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

Daniel E. MichaudORCID

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Spatial/molecular heterogeneity and treatment response in HER2+ early breast cancer: Translational analyses from the DAPHNe trial

Emily Chen, Ilana Miriam Schlam, Kaoru Shimada, Tianyu Li, Esther Ritah Ogayo, Ashka Patel, Janae Davis, Jia‐Ren Lin, Austin Schultz, Madeline G Townsend, Kelly F Zheng, Carlos Wagner S Wanderley, Ricardo Pastorello, Felicia New, Evelyn Metzger, , Adrienne Gropper Waks

The paper analyzes HER2+ breast cancer using multi-platform data to identify molecular predictors of response to neoadjuvant therapy and highlights intra-tumoral heterogeneity and immune exclusion mechanisms.

bioRxiv · Sep 18, 2026 · PreprintCancer Biology

TALAVE in Breast Cancer: BRCA1/2 Mutation-Dependent Immune Remodeling after PARP Inhibition with Limited Checkpoint Engagement

Filipa C. Lynce, Kaoru Shimada, Claudine J. Isaacs, Xue Geng, Edward T. Richardson, Adam Nelson, Candace Bavette Mainor, Mei Wei, Julie Marie Collins, Paula Raffin Pohlmann, Arielle Lutterman Heeke, Kelly F Zheng, Madeline G Townsend, Nicole Swanson, Lauren M. Sloat, , Jennifer L. Guerriero

The paper shows BRCA-mutant breast cancers respond to PARP inhibitors with immune remodeling, but PD-L1 blockade is ineffective due to spatial separation of PD-L1+ cells and PD-1+ T cells.

bioRxiv · Sep 18, 2026 · PreprintCancer Biology

Tumor-myeloid crosstalk drives therapy resistance in localized bladder cancer

Filipe L.F. Carvalho, Ji‐Hyun Lee, Nikolaos Kalavros, Yuzhen Zhou, Daniel E. Michaud, Isabella Stelter, Hiba Siddiqui, Konrad Stawiski, Ramya Ravindranathan, Julia Perera, Shuoshuo Wang, Breanna M. Titchen, Amanda Garza, Kevin Bi, Jihye Park, , Eliezer M. Van Allen

This study identifies tumor-myeloid crosstalk as a driver of cisplatin resistance in bladder cancer and proposes PARP14 inhibition as a therapeutic strategy.

Cell Press Blue · Aug 20, 2026Peer-reviewedCancer Biology

APOE Tumor-Associated Macrophages and CD4-DOCK4 T Cells Reveal Distinct Microenvironmental Features in HER2-Low and HER2-0 Hormone Receptor-Positive Breast Cancer

Carlos Wagner S Wanderley, Daniel E. Michaud, Kenichi Shimada, Adam Nelson, Jingxin Fu, Stuart J. Schnitt, Sara M. Tolaney, Elizabeth Ann Mittendorf, Romualdo Barroso‐Sousa, Adrienne Gropper Waks, Paolo Tarantino, Jennifer L. Guerriero

The paper identifies distinct immune and stromal features in HR+ HER2-low and HER2-0 breast cancers using molecular and multiplexed imaging.

bioRxiv · Sep 4, 2025 · PreprintCancer Biology

Tumor B cell infiltration in platinum-treated advanced urothelial carcinoma

Konrad Stawiski, Júlia Perera‐Bel, Alejo Rodríguez‐Vida, Nuria Juanpere-Rodero, Ji‐Hyun Lee, Daniel E. Michaud, Jennifer L. Guerriero, Kent William Mouw, Aristotelis Bamias, Filipe L.F. Carvalho, Joaquim Bellmunt B

The paper examines how platinum-based chemotherapy affects tumor immune microenvironments in urothelial cancer, finding that memory B cell infiltration correlates with improved survival in cisplatin-treated patients.

bioRxiv · Feb 27, 2025 · PreprintCancer Biology

An estrogen receptor signaling transcriptional program linked to immune evasion in human hormone receptor-positive breast cancer

Kenichi Shimada, Daniel E. Michaud, Yvonne Xiaoyong Cui, Kelly Zheng, Jonathan L. Goldberg, Zhenlin Ju, Stuart J. Schnitt, Ricardo Pastorello, Lukas D. Kania, John Hoffer, Jeremy L. Muhlich, Nhan Hyun, Robert Krueger, Alexander P. Gottlieb, Adam Nelson, , Jennifer L. Guerriero

This study identifies an estrogen receptor signaling program in HR+ breast cancer that suppresses immune responses by reducing T cell infiltration and HLA expression, suggesting therapeutic targets to enhance immunogenicity.

bioRxiv · Nov 23, 2024 · PreprintCancer Biology